AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00263718
Drug: Calcipotriol plus betamethasone dipropionate (LEO 80185) gel
RxNorm normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03246347
Drug: ADT+Docetaxel+Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: combination therapy as listed above
Trial: NCT00846911
Drug: Moxifloxacin (Avelox, BAY12-8039)
RxNorm normalized name: moxifloxacin Injection [Avelox]
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with acute exacerbation of chronic bronchitis for whom the physician decided to prescribe moxifloxacin
Trial: NCT05155540
Drug: recombinant tissue plasminogen activator
RxNorm normalized name: Tissue plasminogen activator, recombinant
DrugBank: Plasminogen (DB16701)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDA approved drug for treatment of acute ischemic stroke within 4.5 hours of strokeonset
Trial: NCT00434876
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine is a second generation antipsychotic medication, which has also recently shown to be associated with properties of mood stabilization in bipolar disorder.
Trial: NCT03035032
Drug: Leuprolide
RxNorm normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Injection
Trial: NCT01250782
Drug: Glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 g/kg/day of dipeptide N (2)-L-Alanyl-L-Glutamine
Trial: NCT01250782
Drug: Physiological serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of physiological serum indistinguishable from active comparator
Trial: NCT02946268
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Change in administration of ropivacaine. Rate, Volume and Interval of bolus altered.
Trial: NCT02303730
Drug: Exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The starting dose of exenatide is 5 ug bid, subcutaneously, for 4 weeks, followed by 10 ug bid, subcutaneously, for 20 weeks. If hypoglycaemia (blood glucose\<2.9 mmol/l or \< 3.9 mmol/l at least 2 times) or serious intolerance occurs, the dose will be adjusted to 5 ug bid, subcutaneously.
Trial: NCT02218372
Drug: Fidaxomicin oral suspension
RxNorm normalized name: fidaxomicin Oral Suspension
DrugBank: Fidaxomicin (DB08874)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants from birth to \< 6 years of age received weight based doses of fidaxomicin oral suspension (32 mg/kg/day with a maximum dose of 400 mg/day divided in 2 doses) 2 times daily for 10 days.
Trial: NCT02537613
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab given weekly during cycle 1, then monthly during cycles 2-6
Trial: NCT02537613
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib given once daily by mouth
Trial: NCT02303730
Drug: insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The starting dose of insulin glargine will depend upon the HbA1c level at screening(HbA1c \<8% use 0.1 -0.2 U/kg per day;HbA1c \>8% use 0.2 -0.3 U/kg per day).~Dose adjustment protocol for insulin glargine (at least 3 determinations of fasting blood glucose per week):~fasting blood glucose(FBG) \> 180 mg/dL(10 mmol/l): add 4 U; FBG 140-180 mg/dL(7.8-10 mmol/l): add 2 U; FBG 126-139 mg/dL(7.0-7.8 mmol/l): add 1 U.~If hypoglycemia, reduce insulin glargine by:~blood glucose \<70mg/dl（3.9mmol/l）: 10%-20%; blood glucose \<40mg/dl（2.2mmol/l）: 20%-40%.
Trial: NCT01086267
Drug: BMS-908662
RxNorm normalized name: BMS-908662
DrugBank: BMS-908662 (DB12854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, escalating doses starting at 25 mg, every 12 hours (Q 12 h), Continuously
Trial: NCT02218372
Drug: Fidaxomicin tablets
RxNorm normalized name: Fidaxomicin Tablets
DrugBank: Fidaxomicin (DB08874)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants aged ≥ 6 years to \< 18 years of age received a 200 mg fidaxomicin tablet 2 times daily for 10 days.
Trial: NCT01086267
Drug: BMS-908662
RxNorm normalized name: BMS-908662
DrugBank: BMS-908662 (DB12854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, (TBD) mg, Q 12 h, Continuously
Trial: NCT01086267
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vial, IV, 400 mg/m² loading dose followed by 250 mg/m² maintenance dose, Weekly, Continuously
Trial: NCT02054572
Drug: [¹⁴C]Etelcalcetide
DrugBank: Etelcalcetide (DB12865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 750 nCi of \[¹⁴C\]etelcalcetide formulated as a single 10 mg dose of etelcaletide in 2 mL liquid solution for bolus intravenous (IV) administration at the end of hemodialysis.
Trial: NCT00003736
Drug: motexafin gadolinium
RxNorm normalized name: Motexafin gadolinium
DrugBank: Motexafin gadolinium (DB05428)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04201834
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: capsule or tablet, 0.5 mg
Trial: NCT00780676
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg tablet by mouth daily
Trial: NCT02218372
Drug: Vancomycin oral liquid
RxNorm normalized name: vancomycin Oral Liquid Product
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants from birth to \< 6 years of age received weight based doses of vancomycin oral liquid (40 mg/kg/day with a maximum dose of 500 mg/day divided in 4 doses) 4 times daily for 10 days.
Trial: NCT02218372
Drug: Vancomycin capsules
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants aged ≥ 6 years to \< 18 years of age received a 125 mg vancomycin capsule 4 times daily for 10 days.
Trial: NCT04087018
Drug: zimberelimab
RxNorm normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zimberelimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1. Participants in each cohort will receive zimberelimab intravenously Q3W. Treatment will continue until progressive disease, unacceptable toxicity, withdrawal of consent, or other reasons for which investigational product discontinuation occurs.
Trial: NCT00320619
Drug: Epsilon-Aminocaproic Acid (EACA)
RxNorm normalized name: Epsilon Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive EACA intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
Trial: NCT00015015
Drug: Dichloroacetate
RxNorm normalized name: Dichloroacetate
DrugBank: Dichloroacetic acid (DB08809)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01913015
Drug: abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT01681537
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01681537
Drug: Mitoxantrone
RxNorm normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01681537
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01681537
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02753283
Drug: denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Semi-annual dose: 60 mg injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
Trial: NCT04301726
Drug: Deutetrabenazine Oral Tablet [Austedo]
RxNorm normalized name: deutetrabenazine Oral Tablet [Austedo]
DrugBank: Tetrabenazine (DB04844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The participants randomized to this group will receive oral deutetrabenazine for 8 weeks. Week 1: 6 mg tab once daily; Week 2: 6 mg tab (BID); Week 3: 9 mg tab (BID); Week 4: 12 mg tab (BID); Week 5: 15 mg (6 mg tab + 9 mg tab BID); Week 6: 18 mg (9 mg tab + 9 mg tab BID); Week 7: 21 mg (9 mg tab + 12 mg tab BID); Week 8: 24 mg (12 mg tab BID).
Trial: NCT04144569
Drug: PD-1 Combined With Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 Combined With Pyrotinib
Trial: NCT01288742
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.
Trial: NCT01288742
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 0.25-mg tablet for 1 day (Trt A)
Trial: NCT01711359
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally
Trial: NCT01711359
Drug: Baricitinib Placebo
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Baricitinib placebo administered orally once daily.
Trial: NCT02517502
Drug: DHA
RxNorm normalized name: DHA
DrugBank: Doconexent (DB03756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 capsules of 400 mg DHA daily
Trial: NCT03539900
Drug: Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NB medication will combine BUPROPION HYDROCHLORIDE (360 mg/day) and NALTREXONE HYDROCHLORIDE (32 mg/day). Taken daily in pill form.
Trial: NCT03469206
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alteplase is used in the intravenous thrombolysis. It catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown.
Trial: NCT03088345
Drug: Vasopressin, Arginine
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
Trial: NCT00671658
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m2 by vein
Trial: NCT00671658
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg by vein
Trial: NCT00671658
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg by vein or by mouth (P.O.)
Trial: NCT00671658
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg intrathecal for Courses 1,3,5,7~3 gm/m2 by vein for Courses 2,4,6,8
Trial: NCT00671658
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 ug/kg subcutaneous injection
Trial: NCT00671658
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 mg/m2 a day by vein
Trial: NCT04602468
Drug: Kaftrio
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The intervention is the same for both study groups. In addition to all the assessments in the standard arm, the advanced arm subjects will undergo spirometry controlled CT, nasal lavage and sputum sample collection.
Trial: NCT00671658
Drug: Pegylated asparaginase
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2000 International units/m2 by vein
Trial: NCT00671658
Drug: Pegfilgrastim
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 6 mg (flat dose) within 72 hrs after completion of chemotherapy
Trial: NCT03696160
Drug: Biktarvy
RxNorm normalized name: Biktarvy
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Integrase inhibitor used to treat HIV-1 infection
Trial: NCT03696160
Drug: Symtuza
RxNorm normalized name: Symtuza
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Protease inhibitor used to treat HIV-1 infection
Trial: NCT00784836
Drug: BG9418 (interferon beta 1-a)
RxNorm normalized name: Interferon beta 1-a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01920061
Drug: PF-05212384 (gedatolisib)
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-05212384 weekly intravenous infusions starting at 90 mg/wk as a 3 week cycle
Trial: NCT01920061
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel intravenous infusions once every 3 weeks starting at 75 mg/m\^2
Trial: NCT01920061
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin intravenous infusions once every 3 weeks starting at 75 mg/m\^2
Trial: NCT01920061
Drug: Dacomitinib
RxNorm normalized name: DACOMITINIB
DrugBank: Dacomitinib (DB11963)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dacomitinib to be taken orally as a continuous once daily regimen at a starting dose of 30 mg
Trial: NCT00877929
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg
Trial: NCT00877929
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
Trial: NCT01466972
Drug: Pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral, 800mg tablet daily per cycle
Trial: NCT00299091
Drug: Efavirenz capsules 200 mg and 600 mg
RxNorm normalized name: efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Modification of doses of efavirenz guided by its plasma concentration (therapeutic drug monitoring)
Trial: NCT00391820
Drug: TD-5108
RxNorm normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02216630
Drug: Adipose Derived Stem Cell (ADSC) Therapy
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients undergo a liposuction where 100 cc of fat are extracted. The ADSCs are then isolated and injected intravenously.
Trial: NCT01921205
Drug: Lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects \<30 kg (LCM oral solution): 4 mg/kg - 6 mg/kg BID ( 8mg/kg/day - 12 mg/kg/day)~Subjects ≥30 kg to \<50 kg (LCM oral solution): 3 mg/kg - 4 mg/kg BID (6 mg/kg/day - 8 mg/kg/day)~Subjects ≥50 kg (LCM tablets): 150 mg - 200 mg BID (300 mg/day - 400 mg/day)
Trial: NCT02918136
Drug: Cortisone Injectable
RxNorm normalized name: cortisone Injectable Product
DrugBank: Cortisone acetate (DB01380)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00842829
Drug: Fentanyl Buccal Tablet (FBT)
RxNorm normalized name: fentanyl Buccal Tablet
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FBTs were self-administered by participants via the oral mucosa. During the open-label dose titration period, participants used 1 to 4 tablets of the 100 mcg or 200 mcg strength to individually titrate upwards to an effective dose through the range of available strengths (i.e. 100, 200, 400, 600, or 800 mcg). For the open-label treatment and continuation periods, single dose tablets at the effective dose identified during the titration period were used. The maximum dose allowed per breakthrough pain (BTP) episode was 800 mcg. On any single day, participants were not to use FBT for more than 4 BTP episodes.
Trial: NCT00287976
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02155725
Drug: Human Fibrinogen concentrate
RxNorm normalized name: Human fibrinogen concentrate, pasteurized
DrugBank: Fibrin (DB16604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection as soon as possible and within 30 min following the start of prostaglandin infusion
Trial: NCT01244971
Drug: Acarbose
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg, 3 times daily
Trial: NCT03618160
Drug: JNJ-64565111
RxNorm normalized name: JNJ-64565111
DrugBank: Efinopegdutide (DB15077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in Cohorts 1 to 3 will receive a single SC low, medium, and high dose of JNJ-64565111 respectively on Day 1, participants in Cohorts 4 to 6 will receive weekly multiple SC low, high and medium dose of JNJ-64565111 respectively on Days 1, 8, 15, and 22, under fasted conditions. Participants in Cohort 7 will receive a single SC medium dose of JNJ-64565111 on Day 1, under fasted conditions.
Trial: NCT01294761
Drug: Raltegravir, Darunavir/r
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: An arm to change the regimen to: raltegravir and darunavir/ritonavir~Prezista naive 2 tabs PC QD, Norvir soft-capsule 1 cap PC QD and Isentress 1 tab BID or Prezista 2 tabs PC BID and Norvir soft-capsule 1 cap PC BID, and Isentress 1 tab BID~from: Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD
Trial: NCT00391911
Drug: N-Acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are assigned to either N-Acetylcysteine or placebo. Dose is weight based Placebo is normal saline or D5W
Trial: NCT02724228
Drug: BMN 111
RxNorm normalized name: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMN 111 will be administered subcutaneously daily.
Trial: NCT00417898
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03216499
Drug: HIF-2alpha Inhibitor PT2385
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00010816
Drug: Herbal remedies
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03685331
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Combination of palbociclib, olaparib, and fulvestrant.
Trial: NCT03685331
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Combination of palbociclib, olaparib, and fulvestrant.
Trial: NCT03685331
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Combination of palbociclib, olaparib, and fulvestrant.
Trial: NCT00333125
Drug: Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav)
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One drop in the study eye(s) once daily, 9 PM, for 6 weeks
Trial: NCT00333125
Drug: Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt)
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One drop in the study eye(s) twice daily for 6 weeks
Trial: NCT03815058
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W.
Trial: NCT02218346
Drug: AG221
RxNorm normalized name: Enasidenib
DrugBank: Enasidenib (DB13874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AG221 in fed and fasted conditions
Trial: NCT01026727
Drug: MPC-4326 plus a 2-3 drug optimized background regimen (OBR)
RxNorm normalized name: milbemycin oxime 2.3 MG / praziquantel 22.8 MG [Interceptor Plus]
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For treatment arm #1: the MPC-4326 dose will be selected based on the inclusion of raltegravir (i.e., will be limited to 300 mg BID) or inclusion of darunavir (i.e., will be assigned 400 mg BID) in the OBR. If both raltegravir and darunavir are included in the OBR for a subject, the subject will be limited to 300 mg BID
Trial: NCT01026727
Drug: 3-4 commercially available antiretroviral drugs
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For treatment arm #2: the antiretroviral regimen, dosage and frequency will be selected by the investigator.